Pharma-Bio Serv, Inc. financial data

Symbol
PBSV on OTC
Location
Dorado, PR
Fiscal year end
31 October
Latest financial report
10-Q - Q2 2025 - 15 Sep 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 661% % -7.1%
Debt-to-equity 20% % -19%
Return On Equity -1% % 88%
Return On Assets -1% % 88%
Operating Margin -7% % 35%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 22,918,092 shares -0.17%
Common Stock, Shares, Outstanding 22,920,442 shares -0.16%
Entity Public Float $13,638,206 USD 0%
Common Stock, Value, Issued $2,352 USD 0%
Weighted Average Number of Shares Outstanding, Basic 22,927,283 shares -0.15%
Weighted Average Number of Shares Outstanding, Diluted 22,937,921 shares -0.1%

Income Statement

Label TTM Value / Value Unit Change %
Revenues $9,184,772 USD -15%
Cost of Revenue $6,297,105 USD -22%
Operating Income (Loss) $658,520 USD 44%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest $113,363 USD 86%
Income Tax Expense (Benefit) $19,555 USD -137%
Net Income (Loss) Attributable to Parent $84,250 USD 90%
Earnings Per Share, Diluted 0 USD/shares -71%

Balance Sheet

Label TTM Value / Value Unit Change %
Marketable Securities, Current $6,767,282 USD 6.7%
Accounts Receivable, after Allowance for Credit Loss, Current $2,015,529 USD -22%
Assets, Current $13,155,656 USD -17%
Property, Plant and Equipment, Net $131,526 USD 623%
Operating Lease, Right-of-Use Asset $72,747 USD -70%
Other Assets, Noncurrent $225,649 USD 80%
Assets $13,585,578 USD -17%
Liabilities, Current $1,658,894 USD -13%
Accrued Income Taxes, Noncurrent $0 USD
Operating Lease, Liability, Noncurrent $0 USD -100%
Liabilities $1,658,894 USD -37%
Accumulated Other Comprehensive Income (Loss), Net of Tax $285,577 USD 13%
Retained Earnings (Accumulated Deficit) $10,533,691 USD -15%
Stockholders' Equity Attributable to Parent $11,926,684 USD -13%
Liabilities and Equity $13,585,578 USD -17%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $416,127 USD -24%
Net Cash Provided by (Used in) Financing Activities $1,742,159 USD -0.45%
Net Cash Provided by (Used in) Investing Activities $438,194 USD -108%
Common Stock, Shares Authorized 50,000,000 shares 0%
Common Stock, Shares, Issued 23,519,672 shares 0%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $2,562,430 USD -170%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $3,957,752 USD -39%
Interest Paid, Excluding Capitalized Interest, Operating Activities $0 USD
Operating Lease, Liability $194,035 USD -44%
Payments to Acquire Property, Plant, and Equipment $163,309 USD 14126%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $51,951 USD 94%
Property, Plant and Equipment, Gross $827,530 USD 24%
Operating Lease, Liability, Current $71,362 USD -56%
Lessee, Operating Lease, Liability, to be Paid, Year Two $29,121 USD -83%
Lessee, Operating Lease, Liability, to be Paid, Year One $174,730 USD 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $9,816 USD -69%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10,000,000 shares 0%
Additional Paid in Capital $1,675,148 USD 2.1%
Preferred Stock, Shares Outstanding 0 shares
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%